Search

Your search keyword '"Mei, Matthew"' showing total 540 results

Search Constraints

Start Over You searched for: Author "Mei, Matthew" Remove constraint Author: "Mei, Matthew"
540 results on '"Mei, Matthew"'

Search Results

1. A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma

3. Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study

6. The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model.

7. Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

8. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma

9. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma

11. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial

12. Multicenter analysis of high-dose chemotherapy (HDCT) regimens for the treatment of patients (pts) with recurrent germ cell tumors (GCTs).

13. Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T‐cell therapy in Philadelphia chromosome‐positive acute lymphoblastic leukaemia

14. Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome‐positive acute lymphoblastic leukemia

18. Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL

20. Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

21. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

24. Coronary artery calcium and cardiovascular outcomes in patients with lymphoma undergoing autologous hematopoietic cell transplantation

26. Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.

27. Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy

28. Anti-CD25 Radioimmunotherapy with BEAM Autologous Hematopoietic Cell Transplantation Conditioning in Hodgkin Lymphoma

30. Real‐world experience of axicabtagene ciloleucel, a CD19‐directed CAR T‐cell therapy, in the second‐line treatment of early relapsed or primary refractory large B‐cell lymphoma.

31. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia

32. Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

34. Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center

38. Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis

39. Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations

41. Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes

42. A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma

43. Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma

44. P1200: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): UPDATED RESULTS FROM THE PHASE 1 WAVELINE-001 STUDY

47. Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

48. Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma

50. Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab

Catalog

Books, media, physical & digital resources